Lineage Cell Therapeutics
LCTX
LCTX
97 hedge funds and large institutions have $52.9M invested in Lineage Cell Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 16 closing their positions.
Holders
97
Holders Change
-11
Holders Change %
-10.19%
% of All Funds
2.14%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
7
Increased
18
Reduced
27
Closed
16
Calls
$138K
Puts
–
Net Calls
+$138K
Net Calls Change
+$140K
Top Buyers
| 1 |
DC
1
Defender Capital
Charlotte,
North Carolina
|
$3.66M |
| 2 |
2
Renaissance Technologies
New York
|
$222K |
| 3 |
3
Jane Street
New York
|
$157K |
| 4 |
4
Northern Trust
Chicago,
Illinois
|
$1.06M |
| 5 |
5
Wells Fargo
San Francisco,
California
|
$249K |
Top Sellers
| 1 |
1
Two Sigma Investments
New York
|
$135K |
| 2 |
2
Morgan Stanley
New York
|
$48K |
| 3 |
3
UBS Group
Zurich,
Switzerland
|
$59K |
| 4 |
4
Bank of New York Mellon
New York
|
$340K |
| 5 |
5
Creative Planning
Overland Park,
Kansas
|
$87K |
